RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis
- PMID: 16373400
- DOI: 10.1096/fj.05-4724fje
RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis
Abstract
Periodontitis is a well-appreciated example of leukocyte-mediated bone loss and inflammation that has pathogenic features similar to those observed in other inflammatory diseases such as arthritis. Resolvins are a new family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammatory signals. Because it is now increasingly apparent that local inflammation plays a critical role in many diseases, including cardiovascular disease, atherosclerosis, and asthma, experiments were undertaken to evaluate the actions of the newly described EPA-derived Resolvin E1 (RvE1) in regulation of neutrophil tissue destruction and resolution of inflammation. The actions of an aspirin-triggered lipoxin (LX) analog and RvE1 in a human disease, localized aggressive periodontitis (LAP), were determined. Results indicate that neutrophils from LAP are refractory to anti-inflammatory molecules of the LX series, whereas LAP neutrophils respond to RvE1. In addition, RvE1 specifically binds to human neutrophils at a site that is functionally distinct from the LX receptor. Consistent with these potent actions, topical application of RvE1 in rabbit periodontitis conferred dramatic protection against inflammation induced tissue and bone loss associated with periodontitis.
Similar articles
-
Resolvin E1 Reverses Experimental Periodontitis and Dysbiosis.J Immunol. 2016 Oct 1;197(7):2796-806. doi: 10.4049/jimmunol.1600859. Epub 2016 Aug 19. J Immunol. 2016. PMID: 27543615 Free PMC article.
-
Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo.J Immunol. 2007 Nov 15;179(10):7021-9. doi: 10.4049/jimmunol.179.10.7021. J Immunol. 2007. PMID: 17982093
-
The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids.Biochem Biophys Res Commun. 2005 Dec 9;338(1):149-57. doi: 10.1016/j.bbrc.2005.07.181. Epub 2005 Aug 10. Biochem Biophys Res Commun. 2005. PMID: 16112645 Review.
-
Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis.Arterioscler Thromb Vasc Biol. 2015 May;35(5):1123-33. doi: 10.1161/ATVBAHA.115.305324. Epub 2015 Mar 19. Arterioscler Thromb Vasc Biol. 2015. PMID: 25792445 Free PMC article.
-
Control of inflammation and periodontitis.Periodontol 2000. 2007;45:158-66. doi: 10.1111/j.1600-0757.2007.00229.x. Periodontol 2000. 2007. PMID: 17850455 Review. No abstract available.
Cited by
-
Resolvin E1 Reverses Experimental Periodontitis and Dysbiosis.J Immunol. 2016 Oct 1;197(7):2796-806. doi: 10.4049/jimmunol.1600859. Epub 2016 Aug 19. J Immunol. 2016. PMID: 27543615 Free PMC article.
-
Distinct Profiles of Specialized Pro-resolving Lipid Mediators and Corresponding Receptor Gene Expression in Periodontal Inflammation.Front Immunol. 2020 Jun 25;11:1307. doi: 10.3389/fimmu.2020.01307. eCollection 2020. Front Immunol. 2020. PMID: 32670289 Free PMC article.
-
Anticytokine therapy for periodontal diseases: Where are we now?J Indian Soc Periodontol. 2009 May;13(2):64-8. doi: 10.4103/0972-124X.55837. J Indian Soc Periodontol. 2009. PMID: 20407652 Free PMC article.
-
Lipid emulsions - Guidelines on Parenteral Nutrition, Chapter 6.Ger Med Sci. 2009 Nov 18;7:Doc22. doi: 10.3205/000081. Ger Med Sci. 2009. PMID: 20049078 Free PMC article. Review.
-
An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption.Br J Pharmacol. 2008 Dec;155(8):1214-23. doi: 10.1038/bjp.2008.367. Epub 2008 Sep 22. Br J Pharmacol. 2008. PMID: 18806821 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials